Tampa, Fla. — Among molecularly targeted agents being developed to treat melanoma, some of the most exciting are anti-CTLA-4 antibodies now being developed by Pfizer and Medarex.
Comorbidities Women With Hair Loss May Experience
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
The Weekly Roundup: March 20-24
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis
Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions
2 Clarke Drive Cranbury, NJ 08512